London Eye Hospital
0800 612 2021
24 HRS
Request a call back
for a Consultation
Name:
Email address:
Phone number:
© 2008 London Eye Hospital Ltd.        10 Harley Street, London, W1G 9PF.        All Rights Reserved.        Registered in the UK No. 05270887.        Disclaimer
Recent research into macular degeneration has resulted in several new drugs now being available.
 They are commonly called intravitreal injections and target the abnormal blood vessels which
cause wet AMD and may benefit many more patients

From the current drugs available for intravitreal injections, our drug of choice is
Lucentis
(ranibizumab) as the results appear to be more encouraging with a significant number of patients
having an improvement in vision which can be maintained for two years.

For many patients however, even after a course of intravitreal injections the vision may remain
poor.  New magnifying implants can significantly improve the vision in many cases.  These are
sometimes called intraocular lenses for the visually impaired or
IOLVIP.
Wet AMD
Only 10% of AMD is of the wet type. A weakness in a
membrane under the retina allows abnormal blood
vessels to grow into the retina. These blood vessels
may bleed or leak fluid causing swelling of the retina
resulting in distortion and rapid deterioration of the
central vision.  Early detection offers the hope of
treatment before too much damage is done, but with
time the leakage stops leaving a dry scar and poor
vision.

Many patients often have a combination of dry and wet
AMD.